🔎 Trials Near Me

Dachaigh › Aillse a' bhroilleach › Virginia

Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Virginia

Tha 78 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann an Virginia.

Bailtean ann an Virginia

Teacsa sgrùdaidh oifigeil (Beurla)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Sentara Martha Jefferson Hospital, Charlottesville
  • Inova Schar Cancer Institute, Fairfax
  • Inova Fair Oaks Hospital, Fairfax
  • agus 5 a bharrachd
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 45 gu 75 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06995898

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Virginia Cancer Specialists, PC, Fairfax
  • Virginia Oncology Associates, Norfolk
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06982521

A Study of PHST001 in Advanced Solid Tumors

  • NEXT Oncology - Virginia, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06840886

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • Bon Secours Virginia Health System, Midlothian
  • Virginia Oncology Associates, Norfolk
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Chesapeake Regional Medical Center, Chesapeake
  • Augusta Health Center for Cancer and Blood Disorders, Fishersville
  • Bon Secours Memorial Regional Medical Center, Mechanicsville
  • agus 7 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

  • Virginia Cancer Specialists, Fairfax
  • Virginia Oncology Associates, Norfolk
  • Shenandoah Oncology, Winchester
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07102381

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  • Virginia Oncology Associates, Norfolk
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07701941

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Virginia Cancer Institute, Richmond
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06369285

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Inova Schar Cancer Institute, Fairfax
  • Virginia Cancer Specialists, PC, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT06324357

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • Inova Schar Cancer Institute, Fairfax
  • Hampton University Proton Therapy Institute, Hampton
A’ fastadhÌre 2
Aoisean 50 agus nas sine · Banairean · Air ùrachadh 29 Sult 2026 · NCT01766297

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

  • Inova Schar Cancer Institute, Fairfax
A’ fastadhÌre 3
Aoisean 19 agus nas sine · Banairean · Air ùrachadh 29 Sult 2026 · NCT05856773

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
  • Shenandoah Oncology ( Site 8004), Winchester
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07060807

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Inova Schar Cancer Institute ( Site 0025), Fairfax
  • Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian
  • VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  • Research Site, Charlottesville
  • Research Site, Fairfax
  • Research Site, Midlothian
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07007559

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
  • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06966700

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Inova, Fairfax
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07214532

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Fort Belvoir
  • Clinical Trial Site, Midlothian
  • Clinical Trial Site, Norfolk
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07085767

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

  • Adult Outpatient Pavilion, Richmond
  • Cellular Immunotherapies and Transplant Department, Richmond
  • VCU Health at Stony Point, Richmond
A’ fastadh
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 22 Sult 2026 · NCT07426913

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

  • University of Virginia Health System, Charlottesville
  • Inova Schar Cancer Institute, Fairfax
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 22 Sult 2026 · NCT07287098

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  • Next Virginia, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 21 Sult 2026 · NCT07524855

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • Bon Secours Cancer Institute at Memorial Regional, Mechanicsville
  • Bon Secours St. Francis Medical Center, Midlothian
  • Bon Secours Cancer Institute at St. Mary's, Richmond
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • NEXT Oncology, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07109726

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Inova Schar Cancer Institute, Fairfax
  • Virginia Cancer Specialists, Fairfax
  • Virginia Oncology Associates, Newport News
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06492616

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

  • Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06797635

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • NEXT Oncology - Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06253871

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

  • NEXT Oncology, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06440005

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • Virginia Cancer Institute, Norfolk
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT05386108

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Midlothian
A’ fastadhÌre 3
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07647328

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • Next Oncology, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT05315700

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Virginia Cancer Specialists-Fairfax, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07287917

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06072612

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

  • NEXT Virginia, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07287995

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Kaiser Permanente-Burke Medical Center, Burke
  • University of Virginia Cancer Center, Charlottesville
  • Augusta Health Center for Cancer and Blood Disorders, Fishersville
  • agus 12 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 60 · Banairean · Air ùrachadh 2 Sult 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • NEXT Virginia, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07029399

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.